Home » Thought Leadership » Blogs

Blogs

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 7 posts
Oncology Market Access Opportunities 2020 NRDL
August 26, 2021 | Blogs

What Market Access Opportunities Exist for Oncology Products in China? An Analysis of Oncology Product Inclusion in the 2020 NRDL

Fourteen oncology drugs were successfully negotiated and included in the 2020 NRDL. As the new prices became effective from March 01, 2021, several key features and trends have been observed.

Cover Image for NRDL Market Access Rare Disease Therapies China 2020 NRDL
August 19, 2021 | Blogs

What Market Access Opportunities Exist for Rare Disease Products in China? An Analysis of Rare Disease Product Inclusion in the 2020 NRDL

The first of two articles investigating market access opportunities in China - CBPartners’ Asia-Pacific Center of Excellence analyzes the opportunities that lie ahead for rare disease products based on 2020 NRDL update inclusion.

ireland in pills
June 2, 2020 | Blogs

2019 NRDL: Insights for Future Pricing Negotiations in China

The 2019 NRDL update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas. CBPartners' blog post examines how these learnings can help shape future NRDL negotiations.

August 13, 2019 | Blogs

China: There’s a New NRDL in Town

Since the Chinese government brought a deluge of reforms to their pharmaceutical sector in 2018, it is no surprise 2019 is shaping up to be another game-changing year. CBPartners' Asia-Pacific Center of Excellence delivered insights about the evolving NRDL in China, as well as strategic considerations for pharmaceutical manufacturers.

June 24, 2019 | Blogs

China’s IPO-Inducing Gamble

CBPartners believes that Hong Kong’s loosening of its IPO listing criteria will result in material growth for the local biotech market; however, in mainland China, infrastructural obstacles remain (e.g., insufficient industry talent) which may slow biotech development regulatory incentives. CBPartners' Asia-Pacific Center of Excellence will continue to monitor this IPO evolution.